Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma

doi:10.1038/s41598-018-31209-8

CNU IR > Pharmacy and Science > Dept. of Biotechnology (including master's program) > Periodical Articles > Item 310902800/32256

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32256

Title:	Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma
Authors:	Wu, Wei-De Chen, Pin-Shern Omar, Hany A. Arafa, El-Shaimaa A. Pan, Hung-Wei Jeng, Jingyueh Hung, Jui-Hsiang
Contributors:	Chia Nan Univ Pharm & Sci, Dept Biotechnol Univ Sharjah, Sharjah Inst Med Res Univ Sharjah, Coll Pharm Ajman Univ, Dept Clin Sci, Coll Pharm Beni Suef Univ, Dept Pharmacol, Fac Pharm Kaohsiung Vet Gen Hosp, Dept Med Educ & Res Chia Nan Univ Pharm & Sci, Drug Discovery & Dev Ctr
Keywords:	Human Hepatoma-Cells Kappa-B Pathway Tumor-Growth Signaling Pathway Cancer Cells Raf/Mek/Erk Pathway Inhibits Migration Over-Expression Fruiting Bodies Cycle Arrest
Date:	2018-08-27
Issue Date:	2019-11-15 15:47:04 (UTC+8)
Publisher:	NATURE PUBLISHING GROUP
Abstract:	Hepatocellular carcinoma (HCC) has been recognized worldwide as one of the major causes of cancer death. The medicinal fungus Antrodia cinnamomea (A. cinnamomea) has been served as a functional food for liver protection. The aim of the present study was to investigate the potential activity of A. cinnamomea extracts as a safe booster for the anticancer activity of sorafenib, a multi-kinase inhibitor approved for the treatment of HCC. The biologically active triterpenoids in the ethanolic extracts of A. cinnamomea (EAC) were initially identified by HPLC/LC/MS then the different extracts and sorafenib were assessed in vitro and in vivo. EAC could effectively sensitize HCC cells to low doses of sorafenib, which was perceived via the ability of the combination to repress cell viability and to induce cell cycle arrest and apoptosis in HCC cells. The ability of EAC to enhance sorafenib activity was mediated through targeting mitogen-activated protein (MAP) kinases, modulating cyclin proteins expression and inhibiting cancer cell invasion. Moreover, the proposed combination significantly suppressed ectopic tumor growth in mice with high safety margins compared to single-agent treatment. Thus, this study highlights the advantage of combining EAC with sorafenib as a potential adjuvant therapeutic strategy against HCC.
???metadata.dc.relation.uri???:	http://dx.doi.org/10.1038/s41598-018-31209-8
Relation:	Scientific Reports, v.8, 12914
Appears in Collections:	[Dept. of Biotechnology (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
10.1007-s13197-018-3148-4.pdf		4992Kb	Adobe PDF	602	View/Open
index.html		0Kb	HTML	1290	View/Open

Loading...